<DOC>
	<DOCNO>NCT02124239</DOCNO>
	<brief_summary>This open-label , uncontrolled , non-randomised multi-centre trial 3 parallel group enrol . The trial include three active treatment group . To eligible inclusion trial , subject must least 10 clinically typical , visible , discrete AKs face , bald scalp arm within contiguous area approximately 250 cm2 sun-damaged skin . There 3 treatment group : ( 1 ) daily application ingenol mebutate gel 0.027 % full face three consecutive day , ( 2 ) regimen bald scalp , ( 3 ) daily application ingenol mebutate gel 0.06 % arm treatment area approximately 250 cm2 four consecutive day .</brief_summary>
	<brief_title>Pharmacokinetics Ingenol Mebutate Gel Actinic Keratosis Under Maximum Use Conditions</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Following verbal write information trial , subject must provide informed consent document signing Informed Consent Form prior trialrelated procedures.2 . Subjects least 10 clinically typical , visible discrete AKs face , approximately 250 cm2 bald scalp area approximately 250 cm2 sundamaged skin arm except back hand . 3 . Subject least 18 year age . 4 . Female subject must either : Nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus ) , Childbearing potential , provide confirm negative urine pregnancy test prior trial treatment , rule pregnancy . 5 . Female subject childbearing potential must willing use effective contraception trial entry completion . Effective contraception define follow : Oral/implant/injectable/transdermal/oestrogenic vaginal ring contraceptive , intrauterine device , condom spermicide , diaphragm spermicide . Abstinence partner 's vasectomy acceptable female agree implement one acceptable method birth control partner change . 1 . Location treatment area ( full face , bald scalp arm ) within 5 cm incompletely heal wound , within 10 cm suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) . 2 . Prior treatment ingenol mebutate gel within last three month . 3 . Lesions treatment area : atypical clinical appearance ( e.g. , hypertrophic , hyperkeratotic cutaneous horn ) and/or , recalcitrant disease ( e.g. , respond cryotherapy two previous occasion ) . 4 . Any abnormal laboratory test medically significant would impact safety subject interpretation trial result , determine investigator 's judgment . 5 . Current enrolment participation investigational clinical trial within 30 day entry trial . 6 . In opinion investigator , subject unlikely comply Clinical Study Protocol ( e.g . alcoholism , drug dependency psychotic state ) . 7 . Subjects QTcF interval &gt; 450 m male 470 ms female relevant pathological change ECG opinion investigator . These interval apply Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>